Abstract
Dendritic cells play a central role in the initiation of the immune response as they are the only antigen-presenting cells able to prime naive T cells. This makes the dendritic cells the vector of choice to use as a cell-based vaccine in immunotherapy. Although there are several strategies to deliver antigen to dendritic cells, the ones transfected with mRNA coding for tumor or viral antigens are able to induce potent antigen specific T-cell responses directed against multiple epitopes. In this review, we report several advances made in the field of anti-tumoral and anti-HIV immunotherapy using mRNA-transfected dendritic cells-based approaches.
MeSH terms
-
Animals
-
Antigen Presentation
-
Antigens, CD / analysis
-
Antigens, Neoplasm / genetics
-
Antigens, Viral / genetics
-
Cells, Cultured / immunology
-
Cells, Cultured / metabolism
-
Clinical Trials, Phase I as Topic
-
Dendritic Cells / classification
-
Dendritic Cells / cytology
-
Dendritic Cells / immunology*
-
Dendritic Cells / metabolism
-
HIV Infections / therapy
-
Humans
-
Immunotherapy, Active*
-
Lymphocyte Activation
-
Mice
-
Myeloid Cells / cytology
-
Neoplasms / therapy
-
RNA, Messenger / genetics*
-
RNA, Neoplasm / genetics
-
RNA, Viral / genetics
-
T-Lymphocytes / immunology
-
Transfection
Substances
-
Antigens, CD
-
Antigens, Neoplasm
-
Antigens, Viral
-
RNA, Messenger
-
RNA, Neoplasm
-
RNA, Viral